Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol.

Pyruvate dehydrogenase kinase (PDK) isoforms are molecular switches that downregulate the pyruvate dehydrogenase complex (PDC) by reversible phosphorylation in mitochondria. We have determined structures of human PDK1 or PDK3 bound to the inhibitors AZD7545, dichloroacetate (DCA), and radicicol. We show that the trifluoromethylpropanamide end of AZD7545 projects into the lipoyl-binding pocket of PDK1. This interaction results in inhibition of PDK1 and PDK3 activities by aborting kinase binding to the PDC scaffold. Paradoxically, AZD7545 at saturating concentrations robustly increases scaffold-free PDK3 activity, similar to the inner lipoyl domain. Good DCA density is present in the helix bundle in the N-terminal domain of PDK1. Bound DCA promotes local conformational changes that are communicated to both nucleotide-binding and lipoyl-binding pockets of PDK1, leading to the inactivation of kinase activity. Finally, radicicol inhibits kinase activity by binding directly to the ATP-binding pocket of PDK3, similar to Hsp90 and Topo VI from the same ATPase/kinase superfamily.

[1]  K. M. Popov,et al.  9 Mitochondrial α-ketoacid dehydrogenase kinases , 1997 .

[2]  T. Roche,et al.  Molecular biology and biochemistry of pyruvate dehydrogenase complexes 1 , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  M. Holness,et al.  Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. , 2003, Biochemical Society transactions.

[4]  L. Korotchkina,et al.  Probing the Mechanism of Inactivation of Human Pyruvate Dehydrogenase by Phosphorylation of Three Sites* , 2001, The Journal of Biological Chemistry.

[5]  K. M. Popov,et al.  Recognition of the inner lipoyl-bearing domain of dihydrolipoyl transacetylase and of the blood glucose-lowering compound AZD7545 by pyruvate dehydrogenase kinase 2. , 2007, Biochemistry.

[6]  Jianchun Dong,et al.  Essential roles of lipoyl domains in the activated function and control of pyruvate dehydrogenase kinases and phosphatase isoform 1. , 2003, European journal of biochemistry.

[7]  P. J. Randle,et al.  Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. , 1974, The Biochemical journal.

[8]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[9]  K. M. Popov,et al.  Amino acid residues responsible for the recognition of dichloroacetate by pyruvate dehydrogenase kinase 2 , 2007, FEBS letters.

[10]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[11]  T. Roche,et al.  Critical role of a lipoyl cofactor of the dihydrolipoyl acetyltransferase in the binding and enhanced function of the pyruvate dehydrogenase kinase. , 1993, Biochemical and biophysical research communications.

[12]  P. Sutphin,et al.  Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy , 2007, Proceedings of the National Academy of Sciences.

[13]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[14]  W. H. Wang,et al.  Anilides of (R)-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase. , 2000, Journal of medicinal chemistry.

[15]  D. Vassylyev,et al.  Crystal structure of an asymmetric complex of pyruvate dehydrogenase kinase 3 with lipoyl domain 2 and its biological implications. , 2007, Journal of molecular biology.

[16]  T. Roche,et al.  Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer , 2007, Cellular and Molecular Life Sciences.

[17]  I. Smirnova,et al.  Inferences about the catalytic domain of P‐type ATPases from the tertiary structures of enzymes that catalyze the same elementary reaction , 1998, FEBS letters.

[18]  L. Reed,et al.  A Trail of Research from Lipoic Acid to α-Keto Acid Dehydrogenase Complexes , 2001, The Journal of Biological Chemistry.

[19]  T. Roche,et al.  Ligand-induced Effects on Pyruvate Dehydrogenase Kinase Isoform 2* , 2006, Journal of Biological Chemistry.

[20]  E. Kilgour,et al.  PDH kinase inhibitors: a novel therapy for Type II diabetes? , 2005, Biochemical Society transactions.

[21]  C. Turck,et al.  Inhibition of branched-chain alpha-keto acid dehydrogenase kinase and Sln1 yeast histidine kinase by the antifungal antibiotic radicicol. , 2002, Molecular pharmacology.

[22]  R. Harris,et al.  Control of pyruvate dehydrogenase kinase gene expression. , 2001, Advances in enzyme regulation.

[23]  T. Roche,et al.  Marked Differences between Two Isoforms of Human Pyruvate Dehydrogenase Kinase* , 2000, The Journal of Biological Chemistry.

[24]  W. M. Teague,et al.  Function of phosphorylation sites on pyruvate dehydrogenase. , 1979, Biochemical and biophysical research communications.

[25]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.

[26]  D. Wigley,et al.  Crystal structure of an N-terminal fragment of the DNA gyrase B protein , 1991, Nature.

[27]  T. Roche,et al.  AZD7545 is a selective inhibitor of pyruvate dehydrogenase kinase 2. , 2003, Biochemical Society transactions.

[28]  K. M. Popov,et al.  Evidence that pyruvate dehydrogenase kinase belongs to the ATPase/kinase superfamily. , 1999, The Biochemical journal.

[29]  A. Nicolas,et al.  An atypical topoisomerase II from archaea with implications for meiotic recombination , 1997, Nature.

[30]  K. M. Popov,et al.  Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart. , 1998, The Biochemical journal.

[31]  J. R. Brown,et al.  Sites of phosphorylation on pyruvate dehydrogenase from bovine kidney and heart. , 1978, Biochemistry.

[32]  G. J. Sale,et al.  Analysis of site occupancies in [32P]phosphorylated pyruvate dehydrogenase complexes by aspartyl-prolyl cleavage of tryptic phosphopeptides. , 1981, European journal of biochemistry.

[33]  J. Berger,et al.  Structural dissection of ATP turnover in the prototypical GHL ATPase TopoVI. , 2005, Structure.

[34]  T. Roche,et al.  Mechanism of pyruvate inhibition of kidney pyruvate dehydrogenasea kinase and synergistic inhibition by pyruvate and ADP. , 1979, The Journal of biological chemistry.

[35]  T. Roche,et al.  Organization of the Cores of the Mammalian Pyruvate Dehydrogenase Complex Formed by E2 and E2 Plus the E3-binding Protein and Their Capacities to Bind the E1 and E3 Components* , 2004, Journal of Biological Chemistry.

[36]  K. M. Popov,et al.  Structure of Pyruvate Dehydrogenase Kinase , 2001, The Journal of Biological Chemistry.

[37]  K. M. Popov,et al.  Interaction between the individual isoenzymes of pyruvate dehydrogenase kinase and the inner lipoyl-bearing domain of transacetylase component of pyruvate dehydrogenase complex. , 2002, The Biochemical journal.

[38]  M. Inouye,et al.  GHKL, an emergent ATPase/kinase superfamily. , 2000, Trends in biochemical sciences.

[39]  A. Harris,et al.  Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. , 2005, Neoplasia.

[40]  T. Roche,et al.  Pyruvate dehydrogenase kinase isoform 2 activity limited and further inhibited by slowing down the rate of dissociation of ADP. , 2004, Biochemistry.

[41]  M. Simon,et al.  Protein histidine kinases and signal transduction in prokaryotes and eukaryotes. , 1994, Trends in genetics : TIG.

[42]  R. Bersin,et al.  Dichloroacetate as metabolic therapy for myocardial ischemia and failure. , 1997, American heart journal.

[43]  C. Ban,et al.  Transformation of MutL by ATP Binding and Hydrolysis A Switch in DNA Mismatch Repair , 1999, Cell.

[44]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[45]  M. Simon,et al.  Coming up for air: HIF-1 and mitochondrial oxygen consumption. , 2006, Cell metabolism.

[46]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[47]  T. Roche,et al.  Facilitated Interaction between the Pyruvate Dehydrogenase Kinase Isoform 2 and the Dihydrolipoyl Acetyltransferase* , 2003, Journal of Biological Chemistry.

[48]  K. M. Popov,et al.  Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. , 1998, The Biochemical journal.

[49]  P. Stacpoole The pharmacology of dichloroacetate. , 1989, Metabolism: clinical and experimental.

[50]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[51]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[52]  K. M. Popov,et al.  Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. , 2001 .

[53]  D. Chuang,et al.  Structure of rat BCKD kinase: Nucleotide-induced domain communication in a mitochondrial protein kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Patel,et al.  Site Specificity of Four Pyruvate Dehydrogenase Kinase Isoenzymes toward the Three Phosphorylation Sites of Human Pyruvate Dehydrogenase* , 2001, The Journal of Biological Chemistry.

[55]  Peter J Bungay,et al.  Regulatory roles of the N-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands. , 2006, Biochemistry.

[56]  D. Chuang,et al.  Crystal structure of pyruvate dehydrogenase kinase 3 bound to lipoyl domain 2 of human pyruvate dehydrogenase complex , 2005, The EMBO journal.

[57]  K. M. Popov,et al.  An Essential Role of Glu-243 and His-239 in the Phosphotransfer Reaction Catalyzed by Pyruvate Dehydrogenase Kinase* , 2001, The Journal of Biological Chemistry.

[58]  S. Curry,et al.  Pharmacokinetics of Dichloroacetate in Adult Patients with Lactic Acidosis , 1997, Journal of clinical pharmacology.

[59]  T. Mak,et al.  Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era? , 2007, Science's STKE.

[60]  T. Roche,et al.  Binding of the Pyruvate Dehydrogenase Kinase to Recombinant Constructs Containing the Inner Lipoyl Domain of the Dihydrolipoyl Acetyltransferase Component (*) , 1995, The Journal of Biological Chemistry.

[61]  K D Cowtan,et al.  Phase combination and cross validation in iterated density-modification calculations. , 1996, Acta crystallographica. Section D, Biological crystallography.

[62]  Randy J. Read,et al.  Pushing the boundaries of molecular replacement with maximum likelihood. , 2001, Acta crystallographica. Section D, Biological crystallography.

[63]  Manuel C. Peitsch,et al.  SWISS-MODEL: an automated protein homology-modeling server , 2003, Nucleic Acids Res..